Adverse drug events and toxicological mechanisms of esketamine: a study based on US Food and Drug Administration Adverse Event Reporting System and network toxicology analysis.
Naunyn-Schmiedeberg's Archives of Pharmacology February 26, 2026 Lu Wang, Rui Xiong, Hengxu Liu et al. 1 citation
Esketamine is a novel antidepressant approved by the US Food and Drug Administration (FDA) in 2019, but comprehensive studies on the post-marketing safety evaluation of esketamine across age groups remain limited. The objective of this study is to provide the age-based pharmacovigilance profile of esketamine and the potential toxicological mechanisms, which may provide insights to inform the...
DOI: 10.1007/s00210-026-05108-z (opens in new tab)
Esketamine
Humans
Antidepressive agents
Age factors
+7